The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2025
Filed:
May. 12, 2022
Applicant:
Kite Pharma, Inc., Santa Monica, CA (US);
Inventors:
Rhine Shen Garcia, Santa Monica, CA (US);
Vicki Plaks, Santa Monica, CA (US);
Assignee:
Kite Pharma, Inc., Santa Monica, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 31/664 (2006.01); A61K 31/675 (2006.01); A61K 31/7076 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 31/675 (2013.01); A61K 31/664 (2013.01); A61K 31/7076 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4211 (2025.01); C07K 16/248 (2013.01); C07K 16/2803 (2013.01); C12N 5/0636 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05);
Abstract
The disclosure provides methods of treating a malignancy comprising administering an effective dose of an immune cell therapy (e.g., a chimeric antigen receptor genetically modified T cell immunotherapy) and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to an immune cell immunotherapy based on the levels of patient and product attributes prior to and after administration of the immunotherapy to the patient.